Insight
October 15, 2026
Template: Employee Health Action Worksheet
When GLP-1 Coverage Changes, What Happens Next?
-
Date posted
Apr 23, 2026
-
Updated
August 2026
-
Clinical and pharmacy expertise from
Jennifer Musick, PharmD, Vice President of Clinical Strategy at Navigate
-
Written by
Brooke Ossenkop, Executive Vice President, Strategy at Navigate
When GLP-1 Coverage Changes, What Happens Next?
For years, we asked members to take charge of their health. They did.
Members sought treatment. They explored new options. They acted on obesity, diabetes, and cardiometabolic risks that had gone unmanaged for years.
GLP-1 demand now exposes a benefits paradox. Employers encouraged action. Now many struggle to afford the response. Rising utilization has reduced the conversation to a false choice: absorb volatile pharmacy costs or restrict access.
Health plans and PBMs must help employer clients find a more durable answer to GLP-1 use.
Employers need more than coverage administration. They need a defensible strategy for connecting pharmacy decisions, clinical support, and member engagement. Members need a coherent experience. Brokers need evidence that GLP-1 support can produce measurable value.
This pressure will shape ASO sales and renewals. Employers and advisors will ask how health plans, TPAs, and PBMs will govern costs, support members through coverage changes, and address clinical needs beyond medication.
A prescription is not a care model.
Access without coordinated clinical and behavioral support can produce erratic adherence, unmanaged side effects, fleeting behavior change, and no long-term plan.
Restricting access may curb immediate pharmacy exposure. It does not resolve obesity, cardiometabolic risk, or employee demand.
The coverage decision is only the beginning.
In the health plan and PBM strategy guide, Jennifer Musick, PharmD, Vice President of Clinical Strategy, explains why a prescription alone is not a care model and how health plans and PBMs can differentiate when employers, brokers, and consultants demand better answers.
The real decision begins after coverage.
Coverage shows what options exist. It does not ensure members understand, get support, or improve.
Health plans and PBMs have pharmacy strategies, claims insights, care management, provider networks, engagement tools, and partners. Yet employers still struggle to see how these investments drive action and measurable health impact.
The challenge is not simply deciding whether to cover GLP-1s. It is connecting the pieces needed to make that coverage decision work.
The 2026 Health Plan and PBM Strategy Guide identifies where coordination breaks down and how health plans and PBMs can create a more connected experience for employers and members.
Healthcare cost escalation is not a data problem. It is a follow-through problem.
A prescription is not a care model
In the Health Plan and PBM Strategy Guide, Jennifer Musick, PharmD, Vice President of Clinical Strategy, explains why a prescription alone is not a care model and how health plans and PBMs can differentiate when employers, brokers, and consultants demand better answers.
See where GLP-1 strategy can break down across the employer and member experience, and what health plans, TPAs, and PBMs must connect to improve adherence, strengthen outcomes, and protect employer and broker confidence.
What health plans, TPAs, and PBMs need to know about changing GLP-1 coverage
Why are employers reconsidering GLP-1 coverage?
Employers are struggling to absorb and forecast rapidly rising utilization. Business Group on Health reports that employer coverage of GLP-1s for obesity fell from 72% in 2025 to 60% in 2026, reflecting broader pressure to contain volatile pharmacy costs. See the 2027 Employer Health Care Strategy Survey.
Is restricting GLP-1 coverage enough to control the underlying risk?
Restricting coverage may reduce immediate pharmacy exposure, but it does not eliminate obesity, cardiometabolic risk, or the need for sustained support. Peterson Health Technology Institute recommends clinically driven eligibility, behavioral and nutritional support, and structured pathways for members who taper or discontinue therapy. Review its employer GLP-1 coverage framework.
What role can health plans, TPAs, and PBMs play?
Health plans, TPAs, and PBMs can help ASO employer clients move beyond a binary choice between absorbing costs and restricting access. By connecting pharmacy strategy, clinical support, member engagement, and personalized communication, they can create a more coherent model around each coverage decision.
Jennifer Musick, PharmD, Vice President of Clinical Strategy at Navigate, will join BeneCard PBF at IFEBP’s 72nd Annual Employee Benefits Conference in New Orleans. Attend their Solutions Spotlight, LiveLife: A Coaching Program for Whole-Person Health, on Monday, October 26, from noon to 12:30 pm.
